Reportedly, ALK mutations or amplifications have been found in approximately 14% of high-risk patients with NB, and a few studies have shown that ALK alone or in combination with other agents can induce NB differentiation (Brodeur et al., 2009). The gene discussed is ALK; the disease is neuroblastoma.